DMK
UTHR icon

David M. Knott’s United Therapeutics UTHR Stock Holding History

David M. Knott’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2.82M Hold
15,300
– – 1.03% 29
2021
Q2 		$2.75M Buy
15,300
+800
+6% +$152K 0.98% 30
2021
Q1 		$2.42M Buy
+14,500
New +$2.42M 1.04% 29

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David M. Knott's UTHR Position: Q3 2021 in Review

David M. Knott held its United Therapeutics (UTHR) position steady in Q3 2021 at 15,300 shares worth $2.82M. The position accounts for 1.03% of the portfolio, ranked #29.

David M. Knott first reported a position in UTHR in Q1 2021 and has held it in 3 quarters since. 426 funds tracked by Wall St. Rank hold UTHR as of Q3 2021.

  • David M. Knott held 15,300 shares of United Therapeutics worth $2.82M as of Q3 2021.
  • David M. Knott left its United Therapeutics share count unchanged in Q3 2021.
  • United Therapeutics made up 1.03% of David M. Knott's portfolio in Q3 2021, its #29 holding.
  • David M. Knott first reported a position in United Therapeutics in Q1 2021 and has held it in 3 quarters since.
  • 426 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2021.

Based on David M. Knott's 13F filing for Q3 2021, filed 12 Nov 2021.